LEPU BIO-B (02157) announced on November 28, 2025, that the company has signed a CDMO service framework agreement with Lepu Medical Technology (Beijing) Co., Ltd. Under the agreement, LEPU BIO-B and/or its subsidiaries will provide CDMO technical services to Lepu Medical and/or its affiliates.

Beyond meeting its own clinical trial and commercialization demands for drug production, the group can now utilize excess capacity more efficiently when suitable business opportunities arise. The board believes that this agreement will optimize the use of surplus production capabilities and generate supplementary cash flow for the group.